NCT05983471View on ClinicalTrials.gov

Efficacy and Safety of ME-015 (Suplatast Tosilate) in Cough Related to Idiopathic Pulmonary Fibrosis (COSMIC-IPF)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 1, 2024

Primary Completion Date

August 31, 2025

Study Completion Date

September 30, 2025

Conditions
Idiopathic Pulmonary FibrosisCoughIPFFibrotic Lung DiseaseChronic CoughCoughing
Interventions
DRUG

ME-015 (Suplatast Tosilate)

Oral capsule form, 200 mg t.i.d. (total 600 mg per 24 hours)

OTHER

Identical placebo

Without active component

Trial Locations (6)

208002

GSVM Medical College, Murari Lal Chest Hospital, Kanpur

411004

ACE Hospital and Research Centre, Pune

522001

Aditya Multi Specialty Hospital, Guntur

590010

KLE's Dr Prabhakar Kore Hospital & Medical Research Centre, Belagavi

641028

Hindusthan Hospital, Coimbatore

700025

Health Point Hospital, Kolkata

Sponsors

Lead Sponsor

Melius Pharma AB
All Listed Sponsors
lead

Melius Pharma AB

INDUSTRY

NCT05983471 - Efficacy and Safety of ME-015 (Suplatast Tosilate) in Cough Related to Idiopathic Pulmonary Fibrosis (COSMIC-IPF) | Biotech Hunter | Biotech Hunter